Novel AML patient selection assay for AMV564, Amphivena's lead therapeutic in hematology, presented at the 62nd American Society of Hematology (ASH) 2020 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 6, 2020 /PRNewswire/ -- Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, today presented data on a novel assay for selection of acute myeloid leukemia (AML)...

from PR Newswire: https://ift.tt/3osU1DE